A California-based biotechnology company, International Stem
Cell Corporation (OTCQB: ISCO) focuses its energies on developing restorative
medicine using stem cell technology. Its innovative parthenogenesis technology
uses human stem cells derived from unfertilized oocytes (eggs), which helps the
company avoid any ethical issues involving the destruction of viable human
embryos. ISCO also produces and markets cells and growth media for therapeutic
research worldwide through its subsidiary, Lifeline Cell Technology. For even
more revenue, the company’s other subsidiary, Lifeline Skin Care, markets and
sells a skin care line that promises rejuvenation and beauty.
In December, Lifeline Skin Care launched its Molecular
Renewal Serum™, just in time for the holidays. This product contains an
impressive nano-compound that works with skin to replenish elasticity and
smoothness. During testing, the serum showed improvement in skin’s resilience
and a decrease in roughness without any negative side effects. The serum also
stimulates collagen production, which lends strength to skin by regrowing dead
skin cells.
That same month, ISCO announced that it had entered a master
clinical research agreement with Florey Institute of Neuroscience and Mental
Health, one of the world’s leading brain research centers. The agreement
cleared the way for scientists to conduct a Phase I/IIa clinical trial studying
the effects of human parthenogenetic stem cells in people with Parkinson’s
disease. Patients are to be enrolled during the first quarter of 2016.
ISCO’s groundbreaking stem cells are created by stimulating
oocytes into dividing themselves into histocompatible cells. The company
strives to create immune matching cells, so that people do not reject the
treatment. So far, ISCO scientists have developed the first line of stem cells
that can be used as therapeutic cells for millions of people with minimal
rejection. The company also aligns itself with the UniStemCell Bank, the first
collection of non-embryonic stem cells, in the hopes of increasing widespread
use and scientific breakthroughs.
With the steady financial growth of ISCO and its
subsidiaries, the company hopes to continue making great strides in
regenerative techniques for eye, liver, and nervous system diseases.
For more information, visit www.internationalstemcell.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
